pre-IPO PHARMA

COMPANY OVERVIEW

Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company, headquartered in the San Francisco Bay area, focused on improving the safety profile of T cell therapies and developing T cell therapies for hematological malignancies and solid tumors. Its core technology platforms center around its proprietary ARTEMIS™ T cell receptor platform and proprietary E-ALPHA® phage display library for the discovery and engineering of human antibodies against intracellular targets via the MHCI complex. The company is developing a pipeline of novel cancer therapeutics targeting intracellular oncogenes as well as cell-surface antigens.


LOCATION

  • Emeryville, CA, USA

  • THERAPEUTIC AREAS

  • Immunology
  • Oncology

  • WEBSITE

    https://www.eurekatherapeutics.com/


    CAREER WEBSITE

    https://www.eurekatherapeutics.com/join-us/


    SOCIAL MEDIA


    INVESTORS

    acorn-campus-ventures acorn-pacific-ventures gp-capital harbinger-venture-capital suma-venture yuan-capital


    PRESS RELEASES


    Jun 6, 2023

    Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS T-Cell Therapy in Pediatric Liver Cancer


    Mar 14, 2023

    Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute


    Oct 18, 2022

    Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS T Cell Therapy for Neuroblastoma


    Oct 17, 2022

    Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatoblastoma with ET140203 ARTEMIS T cells


    Sep 28, 2022

    Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma


    For More Press Releases


    Google Analytics Alternative